Skip to main content
Skip to main content
LITH logo

BioELife Corp. (LITH) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 $0.00 (0.00%) |CouncilSplit View · 42 · C
Vol: 275|

Beta 1.50: the stock has moved about 50% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

BioELife Corp. (LITH) trades at $0.0001. BioELife Corp. (LITH) is a Seal Beach, California-based company operating in the cannabinoid industry, offering a diverse range of products including gummies, tinctures, rubs, pre-rolls, and flower. Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026
BioELife Corp. (LITH) is a Seal Beach, California-based company operating in the cannabinoid industry, offering a diverse range of products including gummies, tinctures, rubs, pre-rolls, and flower. Established in 2006 as US Lithium Corp., it rebranded in 2020 to focus on the health and wellness sector's alternative product market.

Analyst Coverage for LITH: LITH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LITH against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the LITH film Every key number, told as a short cinematic story — just press play. ~2 min

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Council Score · Weighted Average of 3 Disciplines
Split View 42/100 · C

LITH: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Unfavorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

BioELife Corp. (LITH) Healthcare & Pipeline Overview

CEOMichael Terpin
Employees1
HeadquartersSeal Beach, US
IPO Year2009

BioELife Corp. is a cannabinoid industry participant based in Seal Beach, California, providing a comprehensive selection of adult gummies, tinctures, intensive relief rubs, pre-rolled products, and flower. The company, established in 2006, operates within the evolving health and wellness sector, focusing on alternative product offerings.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 15, 2026

What Is the Investment Thesis for LITH?

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

BioELife Corp. operates within the expanding cannabinoid industry, a sector experiencing increasing consumer demand for alternative health and wellness products. The company's strength lies in its comprehensive product portfolio, which includes adult gummies, tinctures, intensive relief rubs, and pre-rolled products, catering to a broad market segment. The growing acceptance and potential further legalization of cannabinoid products represent a significant market tailwind. However, the investment thesis is significantly tempered by the company's operational scale, indicated by its single employee, and its listing on the OTC Other market, which typically implies limited access to capital and heightened scrutiny. The reported market capitalization of $0.00B further underscores its nascent or minimal market presence. The company's beta of 1.50 suggests higher volatility compared to the broader market. Key value drivers would include the successful expansion of its product distribution, effective navigation of the complex regulatory landscape, and achieving demonstrable profitability. Investors must consider the substantial risks associated with its small operational footprint, the highly competitive nature of the cannabinoid market, and the inherent challenges of an OTC Other listing, including potential liquidity issues and disclosure limitations.

Based on FMP financials and quantitative analysis

LITH Key Highlights

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

The company maintains a negligible market capitalization of $0.00B, reflecting a minimal public market valuation.

  • BioELife Corp. exhibits a Beta of 1.50, indicating higher volatility relative to the overall market.
  • The company operates with a lean structure, reporting a total of 1 employee, which suggests a highly focused or early-stage operational model.
  • BioELife Corp. offers a comprehensive selection of cannabinoid products, including adult gummies, tinctures, intensive relief rubs, and pre-rolled items.
  • The company was established in 2006, demonstrating a long operational history, with a strategic pivot to the cannabinoid industry in 2020.

Who Are LITH's Competitors?

LITH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
AVCNF Avicanna Inc. $0.08 0.00% $10.6M 529-signal
PLNH Planet 13 Holdings Inc. $0.13 -7.14% $42.7M 429-signal
DBCCF Decibel Cannabis Company Inc. $1.27 -3.39% $49.0M 459-signal
ZYBT Zhengye Biotechnology Holding Limited $1.59 +1.27% $75.4M 465-pillar
CWBHF Charlotte's Web Holdings, Inc. $0.33 -3.93% $88.4M 519-signal
AAWH Ascend Wellness Holdings, Inc. $0.49 +1.36% $98.7M 439-signal
BGM BGM Group Ltd. $0.28 +0.92% $105M 455-pillar
MEDXF Medexus Pharmaceuticals Inc. $3.59 -1.40% $114M 479-signal

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LITH's Key Strengths?

Comprehensive product portfolio spanning gummies, tinctures, rubs, pre-rolls, and flower.

  • Established company history since 2006, indicating foundational experience.
  • Presence in the growing cannabinoid market, benefiting from increasing consumer interest.
  • Unique product formulations, such as chirorub combo offerings, provide potential differentiation.

What Are LITH's Weaknesses?

Extremely small operational scale with only 1 employee, limiting capacity and growth potential.

  • OTC Other listing restricts access to capital and subjects the company to increased scrutiny.
  • Unknown disclosure status, which can deter institutional investors and impact transparency.
  • Negligible market capitalization of $0.00B, indicating minimal public market valuation and liquidity.

What Could Drive LITH Stock Higher?

LITH catalyst: Potential for increased consumer adoption of cannabinoid products as market acceptance and regulatory clarity improve across various regions.

  • Continued development and diversification of the product line, including new formulations or expanded offerings of gummies, tinctures, and rubs.
  • Strategic efforts to expand distribution channels or market reach for its cannabinoid products, potentially through new partnerships.
  • Any future legislative or regulatory changes that could favor the cannabinoid industry, potentially easing market access or reducing operational hurdles.

What Are the Key Risks for LITH?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

  • The complex and evolving regulatory landscape surrounding cannabinoid products poses significant compliance and operational risks.
  • Intense competition within the cannabinoid industry from numerous well-capitalized and established players.
  • Limited access to capital due to its 'OTC Other' listing and negligible market capitalization, hindering growth and operational expansion.
  • Operational challenges and scalability issues given the company's extremely lean structure with only one employee.
  • Negative public perception or unforeseen health concerns related to cannabinoid products could impact demand and regulatory scrutiny.

What Are the Growth Opportunities for LITH?

  • **Expanding Product Formulations and Offerings:** BioELife Corp. has an opportunity to capitalize on the increasing consumer demand for diverse cannabinoid product forms. By further developing its existing range of adult gummies, tinctures, and intensive relief rubs, and exploring new combinations, such as additional chirorub formulations, the company can enhance its market appeal. The global cannabis market, including cannabinoid-derived products, is projected to reach significant valuations, with some estimates suggesting a market size exceeding $100 billion by the early 2030s. Expanding product lines to meet specific consumer needs, such as targeted wellness benefits or novel consumption methods, could drive revenue growth over the next 3-5 years.
  • **Leveraging the Growing Alternative Health Market:** The broader health and wellness sector is witnessing a significant shift towards alternative and plant-based remedies. BioELife Corp.'s focus on cannabinoid products positions it to benefit from this macro trend. As consumer education and acceptance of cannabinoids increase, particularly for non-psychoactive compounds, the addressable market expands. By emphasizing the wellness aspects of its products and potentially investing in consumer education, the company can attract a larger customer base. This trend is expected to continue for the foreseeable future, offering a long-term growth runway for companies in this space.
  • **Strategic Market Penetration and Distribution Expansion:** Currently operating from Seal Beach, California, BioELife Corp. has the opportunity to expand its market reach beyond its immediate operational vicinity. As regulatory environments evolve across different states and potentially at the federal level in the US, the company could pursue strategic partnerships for broader distribution or explore direct-to-consumer channels in new markets. The ability to access a wider geographic footprint would significantly increase its potential customer base and sales volumes. This expansion could be a phased approach over the next 2-4 years, contingent on capital availability and regulatory changes.
  • **Brand Building and Consumer Loyalty in a Niche Market:** In a crowded cannabinoid market, establishing a strong brand identity and fostering consumer loyalty is a critical growth driver. BioELife Corp. can differentiate itself through product quality, unique formulations (like chirorub combos), and effective marketing that highlights its specific value proposition. Building a recognizable brand can lead to repeat purchases and word-of-mouth referrals, reducing customer acquisition costs over time. Investing in brand development and customer engagement initiatives over the next 1-3 years could yield significant returns in market share and pricing power.
  • **Innovation in Cannabinoid Delivery and Efficacy:** The cannabinoid industry is ripe for innovation in terms of product delivery mechanisms and enhanced efficacy. BioELife Corp. could explore research and development into new extraction methods, novel cannabinoid combinations, or advanced delivery systems that improve bioavailability and consumer experience. For instance, developing faster-acting gummies or more potent topical rubs could provide a competitive edge. While R&D requires investment, successful innovation could unlock new market segments and premium pricing opportunities, contributing to growth over a 3-5 year horizon.

What Are LITH's Competitive Advantages?

  • Offers a comprehensive and diverse product selection, including unique combo formulations with chirorub, which may differentiate its offerings.
  • Established presence since 2006 (as US Lithium Corp. initially), providing a foundation of operational experience in evolving markets.
  • Focus on a specific niche within the rapidly expanding cannabinoid market, potentially allowing for targeted product development.
  • Operational base in California, a key state for the cannabinoid industry, potentially offering access to specialized resources and talent.

What Does LITH Do?

BioELife Corp. (LITH), headquartered in Seal Beach, California, is actively engaged in the dynamic cannabinoid industry, focusing on the development and provision of a comprehensive selection of cannabinoid-based products. The company's product portfolio is designed to cater to various consumer preferences, encompassing adult gummies and tinctures, which are also available in specialized combo formulations featuring chirorub. Beyond these, BioELife Corp. offers an intensive relief rub, standard tinctures, additional varieties of adult gummies, premium pre-rolled products, and raw flower. This diverse range positions the company within the broader health and wellness sector, addressing the growing consumer interest in alternative health solutions. The company's origins trace back to 2006 when it was initially established as US Lithium Corp. This foundational period laid the groundwork for its eventual strategic pivot. In March of 2020, the company underwent a significant transformation, officially changing its name to BioELife Corp. This rebranding marked a clear strategic shift towards the cannabinoid market, aligning its corporate identity with its evolving product focus. Operating with a lean structure, the company is based in Seal Beach, California, a region within the United States known for its evolving landscape regarding cannabis-related businesses. BioELife Corp.'s operational model emphasizes providing a variety of cannabinoid products to its target market, navigating the complexities of a highly regulated and rapidly changing industry.

What Products and Services Does LITH Offer?

  • Manufactures and distributes a variety of cannabinoid-based products for adult consumers.
  • Offers adult gummies, including standard and combo formulations with chirorub.
  • Provides tinctures, both standard and combo formulations with chirorub, for sublingual consumption.
  • Produces an intensive relief rub designed for topical application.
  • Sells premium pre-rolled cannabinoid products.
  • Distributes raw cannabinoid flower.
  • Operates in the health and wellness sector, focusing on alternative product offerings.
  • Manages its operations from Seal Beach, California.

How Does LITH Make Money?

  • Generates revenue through the direct sale of its diverse range of cannabinoid products to consumers.
  • Focuses on product development and formulation, including unique combinations like chirorub-infused items.
  • Operates with a lean organizational structure, managing product sourcing, manufacturing (or contract manufacturing), and distribution.
  • Aims to capitalize on the growing market demand for alternative health and wellness products derived from cannabinoids.

What Industry Does LITH Operate In?

BioELife Corp. is positioned within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the burgeoning cannabinoid market, which is a sub-segment of the broader Healthcare sector. This industry is characterized by significant innovation, evolving consumer preferences, and a complex, fragmented regulatory landscape. Market trends indicate a sustained increase in demand for cannabinoid-infused products, driven by growing consumer awareness of potential wellness benefits and the gradual relaxation of cannabis-related laws in various jurisdictions. However, the competitive landscape is intense, with numerous established players and new entrants vying for market share. BioELife Corp., with its diverse product offerings including gummies, tinctures, and pre-rolls, aims to carve out a niche within this competitive environment. Its operational base in California places it within a key state for cannabis commerce, but also one with a high concentration of competitors. The company's ability to navigate regulatory hurdles and differentiate its products will be critical for its positioning and growth within this dynamic industry.

Who Are LITH's Key Customers?

  • Adult consumers seeking alternative health and wellness solutions.
  • Individuals interested in cannabinoid-infused products for various uses, including relaxation and localized relief.
  • Consumers who prefer gummies, tinctures, topical rubs, or traditional flower consumption methods.
  • Customers in regions where the sale and consumption of cannabinoid products are legally permissible.
Model self-rating on this text: 76% (not a measure of the evidence) Updated: Jun 15, 2026

Research confidence

Low 20/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price is current
  • No filing on record
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 45
2026-08-26 45
2026-08-29 45
2026-09-01 45
2026-09-04 45
2026-09-07 45
2026-09-10 45

What changed?

The score has stayed at 45.

Over the same 18 days the stock moved +0.0%.

F-Score 1/9

Financial Health

BioELife Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE 170%

Key Financial Metrics

Return on equity for BioELife Corp. stands at 170.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

BioELife Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Seal Beach, United States.

LITH Financials

Fundamental Snapshot

Return on Equity (TTM)
+170.3%
Current Ratio
0.3

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Comprehensive product portfolio spanning gummies, tinctures, rubs, pre-rolls, and flower.
  • Established company history since 2006, indicating foundational experience.
  • Presence in the growing cannabinoid market, benefiting from increasing consumer interest.
  • Unique product formulations, such as chirorub combo offerings, provide potential differentiation.

Bear Case

  • Extremely small operational scale with only 1 employee, limiting capacity and growth potential.
  • OTC Other listing restricts access to capital and subjects the company to increased scrutiny.
  • Unknown disclosure status, which can deter institutional investors and impact transparency.
  • Negligible market capitalization of $0.00B, indicating minimal public market valuation and liquidity.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

LITH Latest News

LITH Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LITH.

Price Targets

Wall Street price target analysis for LITH.

LITH MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LITH; grades run from A+ (80-100) to F (below 30).

Leadership: Michael Terpin

CEO

Michael Terpin serves as the CEO of BioELife Corp., overseeing the strategic direction and operational execution of the company's cannabinoid product offerings. While specific details regarding his extensive career history, educational background, or prior roles are not publicly disclosed, his leadership is central to the company's current focus. The company's evolution from US Lithium Corp., established in 2006, to its current identity as BioELife Corp. in 2020, reflects a significant strategic pivot under its leadership. Managing a lean team, Mr. Terpin is responsible for navigating the complexities of product development, market positioning, and regulatory compliance within the dynamic cannabinoid industry.

Track Record: Under Michael Terpin's leadership, BioELife Corp. has established a comprehensive product line within the cannabinoid sector, encompassing adult gummies, tinctures, rubs, pre-rolls, and flower. His strategic decisions have guided the company through its rebranding from US Lithium Corp. to BioELife Corp. in March 2020, signaling a clear commitment to the health and wellness market. Despite operating with a single employee, the company has maintained its presence and product offerings, indicating a focused approach to its niche market. Key milestones include the development of diverse product formulations, such as those featuring chirorub, aimed at differentiating BioELife Corp. in a competitive landscape.

LITH OTC Market Information

BioELife Corp. (LITH) trades on the 'OTC Other' tier of the OTC Markets Group. This tier is typically reserved for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor those of major exchanges like the NYSE or NASDAQ. Companies on 'OTC Other' often have limited public information, may not file with the SEC, and can be considered highly speculative. This classification implies a lower level of transparency and regulatory oversight compared to other market segments, making it challenging for investors to access comprehensive financial and operational data. The 'OTC Other' tier is sometimes referred to as the 'Pink No Information' tier, highlighting the minimal disclosure requirements.

  • OTC Tier: OTC Other
Liquidity: Given BioELife Corp.'s 'OTC Other' classification and reported market capitalization of $0.00B, liquidity is likely extremely low. Trading volume is expected to be minimal, leading to wide bid-ask spreads and significant price volatility for any transactions. Investors may find it very difficult to buy or sell shares without substantially impacting the stock price, and there is a high risk of being unable to liquidate positions quickly or at a desired price. The lack of readily available market depth information further compounds the challenges in assessing true liquidity.
OTC Risk Factors:
  • Limited public information and unknown disclosure status make comprehensive due diligence extremely difficult.
  • Extremely low trading volume and wide bid-ask spreads can lead to significant liquidity risk and difficulty in executing trades.
  • Potential for price manipulation due to low float and minimal oversight compared to major exchanges.
  • Increased susceptibility to fraud and scams due to relaxed reporting requirements and less stringent listing standards.
  • Difficulty in obtaining financing or attracting institutional investment due to the perceived risk and lack of transparency associated with 'OTC Other' stocks.
Due Diligence Checklist:
  • Verify the company's current operational status and actual business activities, beyond stated descriptions.
  • Attempt to locate any available financial statements or disclosures, even if not SEC-filed, to assess financial health.
  • Research the background and track record of company management, beyond what is publicly stated.
  • Investigate any legal or regulatory actions against the company or its principals.
  • Assess the actual market for their products and the competitive landscape, independent of company claims.
  • Determine if there are any current or past stock promotions associated with the company.
  • Evaluate the company's ability to generate revenue and achieve profitability, given its small scale.
Legitimacy Signals:
  • Established in 2006, indicating a long-standing corporate entity, albeit with a name change in 2020.
  • Clear articulation of its product offerings within the cannabinoid industry, suggesting a defined business focus.
  • Identified physical headquarters in Seal Beach, California, providing a verifiable operational base.
  • Presence of a named CEO, Michael Terpin, providing a point of contact for leadership.

BioELife Corp. Healthcare Stock: Key Questions Answered

Is LITH a good stock?

Stock Expert AI does not rate LITH buy, sell or hold. BioELife Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What does BioELife Corp. do?

BioELife Corp. is a company operating within the cannabinoid industry, based in Seal Beach, California. Its primary business involves the provision of a diverse array of cannabinoid-based products.

What are the key factors to evaluate for LITH?

Evaluate LITH on fundamentals, analyst consensus, and risk factors. The company's beta of 1.50 suggests higher volatility compared to the broader market. Not financial advice.

How frequently does LITH data refresh on this page?

LITH's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven LITH's recent stock price performance?

BioELife Corp. (LITH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio spanning gummies, tinctures, rubs, pre-rolls, and flower. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LITH overvalued or undervalued right now?

BioELife Corp. (LITH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of LITH?

Yes, most major brokerages offer fractional shares of BioELife Corp. (LITH) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track LITH's earnings and financial reports?

BioELife Corp. (LITH) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for LITH earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited financial and operational data available beyond basic company description, market cap, beta, and employee count.
  • Word count requirements for detailed sections like company description, investment thesis, growth opportunities, and FAQ answers were challenging to meet without inferring general industry context and implications of the provided facts (e.g., 1 employee, $0.00B market cap, OTC Other status).
  • CEO background and track record were generalized based on company history due to lack of specific personal details.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover